02487 CUTIA-B
- 12.820
- -0.180-1.38%
CUTIA-B News
Hong Kong stock market volatility | Ke D-B (02487) rose more than 5% in early trading, pipeline progress exceeded expectations, institutions said next year is a key business year for the company.
Ke Di-B (02487) rose more than 5% in early trading. As of the time of publication, it has risen 3.87%, at a price of HK$12.34, with a turnover of HK$2.3564 million.
CUTIA-B: SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2023 ANNUAL REPORT
CICC: Reaffirmed the "outperform" rating for Sea Ltd (02487), with the target price raised to HK$15.2.
CLSA expects Kadi will launch three core products, CU-40102, CU-10201, and CU-30101, over the next 12 months.
Kadil-B (02487.HK): Skincare growth exceeding expectations accounts for nearly half, and progress of maifeng cream exceeds expectations as the fastest in the market. Dual-track advancement of commercialization and pipeline.
The company disclosed the interim performance of 24H1: Income: 24H1 income of 95.58 million yuan, +178%, of which Q2 income is approximately 61.48 million yuan (a quarter-on-quarter increase of approximately 80%), continuing the high-growth trend, including during the 618 promotional period.
Keystone Corporation B (02487.HK): The first half of the year's earnings increased by 178.3% year-on-year to 95.6 million yuan.
On August 29th, Code-B (02487.HK) announced that for the six months ended June 30, 2024, the income increased by approximately 178.3% YoY to approximately RMB 95.6 million; the gross margin increased by approximately 5 percentage points from approximately 48% for the six months ended December 31, 2023 to approximately 53% for the six months ended June 30, 2024. For the six months ended June 30, 2024, the adjusted net loss amounted to approximately RMB 0.161 billion (adjusted according to non-international financial reporting standards). The group continues to optimize operational efficiency, and the proportion of adjusted net loss to income is
Keidi-B (02487) released its interim performance, with a shareholder net loss of 0.201 billion yuan, a year-on-year decrease of 87.75%.
Kedi-B (02487) released its interim performance for the six months ending on June 30, 2024, and the group achieved revenue...
Performance: Codemasters (02487.HK) half-year loss narrowed to 0.201 billion RMB.
Keidi-B (02487.HK) announced its interim performance ending in June this year, with revenue of 95.575 million RMB, an increase of 178.3% year-on-year. The loss narrowed to 0.201 billion RMB, compared to a loss of 1.64 billion RMB in the same period last year; loss per share was 0.66 RMB. No dividend will be distributed.
CUTIA-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024
HK stocks market: Biotech company Kedi-B (02487) rose more than 5% in the afternoon. The clinical trial results of their treatment for androgenic alopecia in China phase III were showcased.
KeDi-B (02487) rose more than 5% in the afternoon, as of the deadline, up by 3.97%, trading at 12.06 Hong Kong dollars, with a turnover of 11.6842 million Hong Kong dollars.
Keddie - B (02487.HK) China III clinical trial results for androgenetic alopecia treatment products were presented.
Kodide - B (02487.HK) announced that the results of the Phase III clinical trial of its treatment for androgenetic alopecia product CU-40102 in China were accepted for presentation as an electronic poster at the 8th Hair Academic Conference of the Chinese Medical Association.
Kedai-B(02487.HK): CU-40102 (topical finasteride spray) China Phase III clinical trial results were accepted and presented at the 8th Annual Hair Conference of the Chinese Medical Association in the form of an e-poster.
Great Wall Pharmaceuticals on August 29th, Science Di-B (02487.HK) announced that the group's treatment for androgenetic alopecia product CU-40102 (topical finasteride spray) China Phase III clinical trial results were presented in electronic poster format at the 8th National Hair Academic Conference of the Chinese Medical Association. CU-40102 is the world's first and only topical finasteride product approved for the treatment of androgenetic alopecia, as well as the first topical finasteride product accepted by the National Medical Products Administration (NMPA) for NDA. CU-40102 in China's Phase III registration clinical
Kepei-B (02487.HK) held a board of directors meeting on August 29 to consider and approve the interim performance.
Codip-B (02487.HK) announced on August 19 that it will hold a board of directors meeting on Thursday, August 29, 2024, to consider and approve the company and its subsidiaries' mid-term performance ended June 30, 2024. Additionally, the meeting will discuss the proposed interim dividend (if any) and handle other matters.
CUTIA-B: DATE OF BOARD MEETING
Hong Kong stocks changed | Keddie-B (02487) rose more than 4% in early trading. The application for the CU-30101 pharmaceutical market access license was accepted and the progress exceeded market expectations.
Kepei-B (02487) rose more than 4% in early trading. As of press time, it has risen by 3.6%, and is at HKD 8.05, with a turnover of HKD 2.9247 million.
CICC: Maintains outperform rating for KeDuoB(B02487), target price lowered to HKD 11.
Zhongjin believes that the company has good commercialization capabilities, and various pipelines are expected to land in 2H24-25, bullish on the long-term growth space.
Kepei-B (02487.HK): The application for listing of Biaomaguan pipeline has been accepted. Company buybacks demonstrate confidence.
Recently, the company announced that the application for the listing license of CU-30101 (local topical lidocaine and prilocaine cream) has been accepted by the National Medical Products Administration. In addition, as of July 30, the company has repurchased a total of 58.58 shares.
Fangzheng Securities: Liding Double Lidocaine Ointment's listing application has been accepted. Maintain a 'recommended' rating for Kodis-B (02487).
Fangzheng Securities stated that Kedi-B (02487) has strong short-term commercialization drive, strong high-growth potential and long-term research and development with leading high barriers. There are multiple possibilities for exceeding expectations in various dimensions.
Ketpep-B (02487.HK): Lidocaine and Prilocaine Cream for topical anesthesia has received market approval for launch, progress exceeding market expectations.
Event: The application for the launch of a medicinal plaster product has been accepted, and the progress has exceeded the market's expectations. The company has announced that the CU-30101 (local application of lidocaine and prilocaine cream) pharmaceutical has obtained the market launch approval application accepted by the National Medical Products Administration, and progress is expected to be
SciClone Pharmaceuticals (02487.HK): Lading Dual Card Procaine Ointment Listed Application Accepted, Repurchasing Shares Demonstrates Confidence.
Event: The company's application to market CU-30101 (local external lidocaine procaine cream) has been accepted by the National Medical Products Administration according to the announcement. Lidocaine and procaine are the key ingredients.
China Accepts Cutia Therapeutics' Application for Skin Anesthetic
Analysis
Price Target
No Data
